Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]
Amer M Zeidan,1,* Sanam Loghavi2,* 1Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA; 2Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this workCorresponde...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | Blood and Lymphatic Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/unveiling-the-mysteries-of-molecular-testing-in-aml-a-guide-for-oncolo-peer-reviewed-fulltext-article-BLCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Amer M Zeidan,1,* Sanam Loghavi2,* 1Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA; 2Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this workCorrespondence: Amer M Zeidan, Yale Comprehensive Cancer Center and Smilow Cancer Hospital, 37 College Street, 1st floor, New Haven, CT, 06510, USA, Email amer.zeidan@yale.eduAbstract: In the first episode of the AML Expert Series, titled Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists, experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular diagnostics in acute myeloid leukemia (AML). The discussion traces the shift from morphology- and immunophenotype-based classification to genomics-driven stratification, catalyzed by advancements in next-generation sequencing (NGS). Discussants emphasize the clinical importance of identifying key genetic mutations—such as FLT3, IDH1/2, TP53, NPM1, KMT2A, and NUP98—to inform prognosis and guide use of targeted therapies. They review the sensitivity and applications of testing modalities including Sanger sequencing, NGS, PCR, and capillary electrophoresis, and highlight how combining DNA and RNA analyses enhances detection of both mutations and gene fusions. Practical insights are offered on assay selection, test interpretation, and turnaround times, noting that while NGS is generally adequate for most targets, single-gene PCR may be needed for urgent decision-making. The episode concludes by underscoring the need for oncologists to partner with pathologists and review test coverage data to ensure appropriate molecular profiling. These insights support the integration of precise molecular diagnostics into routine AML management, enhancing personalized therapy and improving clinical outcomes.Keywords: acute myeloid leukemia, IDH inhibitors, precision medicine, cytogenetics, next generation sequencing, IDH1-mutation |
|---|---|
| ISSN: | 1179-9889 |